Rexahn Pharmaceuticals Completes Patient Enrollment In Serdaxin Phase IIb Clinical Trial For Major Depressive Disorder

Rexahn Pharmaceuticals Completes Patient Enrollment In Serdaxin Phase IIb Clinical Trial For Major Depressive Disorder

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical platform pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment in its Phase IIb clinical suit of Serdaxin® to treat major depressive disorder (MDD). The randomized, double concealment, and placebo-controlled study began enrollment in January 2011 and enrolled a aggregate of 300 patients at approximately 40 sites in the United States. The Company expects to account preliminary findings from the trial in after the proper time 2011. The primary efficacy endpoint of the study is the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS).

"We are to a high degree excited by the speed at which we've completed enrollment in our Phase IIb wretchedness for Serdaxin and believe that this farther validates the current unmet need instead of an effective treatment for major depressive jumble"

"We are very excited by the speed at which we've completed enrollment in our Phase IIb unhappiness for Serdaxin and believe that this farther validates the current unmet need with respect to an effective treatment for major depressive ailment," said Rick Soni, President and Chief Operating Officer. "We watch forward to completing the trial and announcing preparatory step results before the end of the year."

About Serdaxin®

Serdaxin® is a potential market-leading CNS neuroprotective agent and antidepressant. Rexahn is generally investigating Serdaxin as a treatment for depression, in a large Phase II clinical pain. Serdaxin may achieve greater and broader curative coverage and appears to be secure and well tolerated without the manner of serious side effects that are commonly linked to popularly marketed antidepressant drugs, such as selective serotonin uptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), and tricyclic antidepressants (TCA). Serdaxin has a well-established, thoroughly good human safety profile. In preclinical studies, Serdaxin had first brunt of action in less than couple days.

Based on its novel mechanical construction as a dual serotonin and dopamine enhancer, it is a potential treatment for multiple CNS disorders to which place these neurotransmitters are depleted or implicated in CNS-based illnesses, so as Parkinson's disease (PD). Serdaxin has the in posse to address both non-motor and motor events of PD by serving as a neuroprotective agent and addressing loss of dopaminergic neurons that lead to overthrow of control of movements; and more remote, enhancing serotonin and dopamine levels that are involved in gloom and mood disorders. Rexahn has multiple clinical programs planned in opposition to investigating Serdaxin in the treatment of foreboding disorders, Parkinson's disease, Alzheimer's illness and neurodegenerative illnesses, neuroprotection and biodefense uses.